Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ADMA Biologics faces securities fraud investigation after short-seller report triggers stock plunge.
ADMA
$8.86
+$0.18 +2.07%

ADMA Biologics faces securities fraud investigation after short-seller report triggers stock plunge.

Market News
30 Apr 2026
PRNewsWire
View Source
Bearish
pluang ai news

Pomerantz LLP is investigating ADMA Biologics for possible securities fraud following a short report by Culper Research accusing the company of inflating growth through channel stuffing and undisclosed related-party sales. After the report, ADMA's stock dropped sharply, losing over 30% in value across two days. Cantor Fitzgerald also downgraded ADMA citing inadequate company response. The investigation could lead to legal action affecting investors and the company's reputation.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App